To explore the mechanism and experimental verification of ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds in the treatment of aplastic anemia based on network pharmacology

To explore the mechanism and experimental verification of ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds in the treatment of aplastic anemia based on network pharmacology | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article To explore the mechanism and experimental verification of ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds in the treatment of aplastic anemia based on network pharmacology Ke Zheng, Yang Song, Jinxuan Han, JingJing Han, Shuangshuang Duan, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8338298/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 7 You are reading this latest preprint version Abstract Background Aplastic anemia is a life-threatening condition that leads to anemia, bleeding and infection. We used network pharmacology to investigate the mechanism of action of Ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds in the treatment of aplastic anemia. Methods In this study, HERB and TCMSP databases were used to obtain Ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds, and ADMET lab3.0 was used to screen the active ingredients. The molecular structure was obtained by using PubChem database, and the active component Target was further predicted by Swiss Target Prediction. GeneCards and DisGeNET databases were used to obtain related targets, and the intersection of active ingredient prediction targets and disease targets was obtained through Origin 2023 Academic software. The PPI interaction network of intersecting targets was constructed using STRING platform, and the potential key targets was screened by Cytoscape software. Again, use Cytoscape software to build ingredient-targets and find the core active ingredients. GO functional enrichment analysis and KEGG pathway enrichment analysis were conducted through Metascape database. Finally, molecular docking was performed to further clarify the components and target action mechanism of its therapeutic effect. The levels of HIF-1 signaling pathway were detected by Western blotting (WB) and qRT-PCR. Results A total of 233 active ingredients were screened, including 438 predicted targets, 2964 disease targets and 94 intersection targets were screened for aplastic anemia treatment. The core targets were STAT3, PIK3CB, PIK3CA, PDGFR, PDGFRA, EGFRH, EP300, ESR1, PTPN1 and PIK3CD. GO and KEGG enrichment analysis mainly pointed to the functions related to the positive regulation of external stimulus response, etc. The signal transduction involved mainly included the pathways such as HIF-1 signaling pathway. WB and qRT-PCR results showed that the levels of HIF-1a, BNIP3, TXNIP and GLUT1 in different dose groups were significantly different from those in model group. Conclusion Ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds may play a role in the treatment of aplastic anemia through HIF-1 signaling pathway, which initially reveals the potential mechanism of action in the treatment of aplastic anemia, and provides a theoretical basis for further research and clinical application. Network pharmacology Ginsenoside Rb1 Angelica polysaccharide astragaloside IV aplastic anemia mechanism Full Text Additional Declarations No competing interests reported. Supplementary Files Wb.zip Dataandmaterials.zip Cite Share Download PDF Status: Under Review Version 1 posted Reviewers agreed at journal 26 Apr, 2026 Reviewers agreed at journal 23 Mar, 2026 Reviewers invited by journal 19 Feb, 2026 Editor invited by journal 05 Feb, 2026 Editor assigned by journal 28 Jan, 2026 Submission checks completed at journal 27 Jan, 2026 First submitted to journal 27 Jan, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8338298","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":594168723,"identity":"abeb810f-6aed-4fa6-be3e-bc3b4fea3038","order_by":0,"name":"Ke Zheng","email":"","orcid":"","institution":"Jining Medical University","correspondingAuthor":false,"prefix":"","firstName":"Ke","middleName":"","lastName":"Zheng","suffix":""},{"id":594168725,"identity":"ab262bd3-8973-4f54-a581-ddfebf3efb74","order_by":1,"name":"Yang Song","email":"","orcid":"","institution":"Weifang Medical University","correspondingAuthor":false,"prefix":"","firstName":"Yang","middleName":"","lastName":"Song","suffix":""},{"id":594168731,"identity":"45c9fd48-21a4-4ae8-922b-748f639b4a68","order_by":2,"name":"Jinxuan Han","email":"","orcid":"","institution":"Weifang Medical University","correspondingAuthor":false,"prefix":"","firstName":"Jinxuan","middleName":"","lastName":"Han","suffix":""},{"id":594168734,"identity":"04319bd5-cdf6-41fd-8db0-b1ee3496f965","order_by":3,"name":"JingJing Han","email":"","orcid":"","institution":"Jining First People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"JingJing","middleName":"","lastName":"Han","suffix":""},{"id":594168735,"identity":"515a50e2-a0ce-44f8-8788-1685f5bf249a","order_by":4,"name":"Shuangshuang Duan","email":"","orcid":"","institution":"Tengzhou Central People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Shuangshuang","middleName":"","lastName":"Duan","suffix":""},{"id":594168736,"identity":"33223162-4668-41fb-8d34-fabdb358c954","order_by":5,"name":"Chunlei Xin","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA2UlEQVRIie3PoQrCYBDA8RsH38rpquMTn+HGYBiGPosMlgxazMJgSbDqW/gI6qEW0WowCIJZsRgMiiAW2WYzfD8u3p/jAAzjH+FroAqIs8OZw0bhhABV5I06cVT00DMBCjSd51Y/b51Xpdm1m+7JscH3Q54i2LKYZCVuUo70OD2Rm0Dr2OZ9GSiOd1mJgxRgKRViAfHbfEKoUJCZqHfSFCvVdRarn5d8riAqDUUSNyFf00aoIgq9AceRyvuFt2vvSj2pOcPt5XC7hw3HlmVm8uW739YNwzCMbx71lz4K5VJsGAAAAABJRU5ErkJggg==","orcid":"","institution":"Jining First People's Hospital","correspondingAuthor":true,"prefix":"","firstName":"Chunlei","middleName":"","lastName":"Xin","suffix":""}],"badges":[],"createdAt":"2025-12-11 15:28:21","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8338298/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8338298/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":103237855,"identity":"8bb7fdad-cfc8-4537-b145-de65473186c4","added_by":"auto","created_at":"2026-02-23 13:29:50","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":778175,"visible":true,"origin":"","legend":"","description":"","filename":"ToexplorethemechanismandexperimentalverificationofginsenosideRb1AngelicapolysaccharidecombinedwithastragalosideIVcompoundsinthetreatmentofaplastica.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8338298/v1_covered_802409bb-9b72-4a3b-ae6b-ec7b748b32ad.pdf"},{"id":103237853,"identity":"f92445d3-2cd8-4181-b267-3d04f21523e6","added_by":"auto","created_at":"2026-02-23 13:29:44","extension":"zip","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":6127647,"visible":true,"origin":"","legend":"","description":"","filename":"Wb.zip","url":"https://assets-eu.researchsquare.com/files/rs-8338298/v1/9ed83494567f6c6f2bc7b393.zip"},{"id":103237854,"identity":"6b94399a-11c8-43d0-ac60-d80db7cbdfff","added_by":"auto","created_at":"2026-02-23 13:29:44","extension":"zip","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":23448633,"visible":true,"origin":"","legend":"","description":"","filename":"Dataandmaterials.zip","url":"https://assets-eu.researchsquare.com/files/rs-8338298/v1/4ea2fa7c803df24f7c399211.zip"}],"financialInterests":"No competing interests reported.","formattedTitle":"To explore the mechanism and experimental verification of ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds in the treatment of aplastic anemia based on network pharmacology","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-complementary-medicine-and-therapies","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcam","sideBox":"Learn more about [BMC Complementary Medicine and Therapies](https://bmccomplementmedtherapies.biomedcentral.com/)","snPcode":"","submissionUrl":"","title":"BMC Complementary Medicine and Therapies","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Network pharmacology, Ginsenoside Rb1, Angelica polysaccharide, astragaloside IV, aplastic anemia, mechanism","lastPublishedDoi":"10.21203/rs.3.rs-8338298/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8338298/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eAplastic anemia is a life-threatening condition that leads to anemia, bleeding and infection. We used network pharmacology to investigate the mechanism of action of Ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds in the treatment of aplastic anemia.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eIn this study, HERB and TCMSP databases were used to obtain Ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds, and ADMET lab3.0 was used to screen the active ingredients. The molecular structure was obtained by using PubChem database, and the active component Target was further predicted by Swiss Target Prediction. GeneCards and DisGeNET databases were used to obtain related targets, and the intersection of active ingredient prediction targets and disease targets was obtained through Origin 2023 Academic software. The PPI interaction network of intersecting targets was constructed using STRING platform, and the potential key targets was screened by Cytoscape software. Again, use Cytoscape software to build ingredient-targets and find the core active ingredients. GO functional enrichment analysis and KEGG pathway enrichment analysis were conducted through Metascape database. Finally, molecular docking was performed to further clarify the components and target action mechanism of its therapeutic effect. The levels of HIF-1 signaling pathway were detected by Western blotting (WB) and qRT-PCR.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eA total of 233 active ingredients were screened, including 438 predicted targets, 2964 disease targets and 94 intersection targets were screened for aplastic anemia treatment. The core targets were STAT3, PIK3CB, PIK3CA, PDGFR, PDGFRA, EGFRH, EP300, ESR1, PTPN1 and PIK3CD. GO and KEGG enrichment analysis mainly pointed to the functions related to the positive regulation of external stimulus response, etc. The signal transduction involved mainly included the pathways such as HIF-1 signaling pathway. WB and qRT-PCR results showed that the levels of HIF-1a, BNIP3, TXNIP and GLUT1 in different dose groups were significantly different from those in model group.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eGinsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds may play a role in the treatment of aplastic anemia through HIF-1 signaling pathway, which initially reveals the potential mechanism of action in the treatment of aplastic anemia, and provides a theoretical basis for further research and clinical application.\u003c/p\u003e","manuscriptTitle":"To explore the mechanism and experimental verification of ginsenoside Rb1, Angelica polysaccharide combined with astragaloside IV compounds in the treatment of aplastic anemia based on network pharmacology","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-23 13:29:39","doi":"10.21203/rs.3.rs-8338298/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"reviewerAgreed","content":"97526477693478192951361877310432096612","date":"2026-04-26T11:26:31+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"21095094489252436962745565088123523054","date":"2026-03-23T05:20:30+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-02-19T08:48:39+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2026-02-05T09:45:17+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-01-28T11:09:53+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2026-01-27T13:47:08+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Complementary Medicine and Therapies","date":"2026-01-27T13:29:19+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-complementary-medicine-and-therapies","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcam","sideBox":"Learn more about [BMC Complementary Medicine and Therapies](https://bmccomplementmedtherapies.biomedcentral.com/)","snPcode":"","submissionUrl":"","title":"BMC Complementary Medicine and Therapies","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"0cd99f50-58ea-4ea7-a32e-862702f58110","owner":[],"postedDate":"February 23rd, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-02-23T13:29:39+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-23 13:29:39","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8338298","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8338298","identity":"rs-8338298","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}